Protagonist Therapeutics, Inc Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Protagonist Therapeutics, Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2015 to Q2 2024.
  • Protagonist Therapeutics, Inc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $8.94M, a 7.2% increase year-over-year.
  • Protagonist Therapeutics, Inc Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $31.7M, a 15.6% increase year-over-year.
  • Protagonist Therapeutics, Inc annual Share-based Payment Arrangement, Expense for 2023 was $29.3M, a 21% increase from 2022.
  • Protagonist Therapeutics, Inc annual Share-based Payment Arrangement, Expense for 2022 was $24.2M, a 47.6% increase from 2021.
  • Protagonist Therapeutics, Inc annual Share-based Payment Arrangement, Expense for 2021 was $16.4M, a 108% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $31.7M $8.94M +$601K +7.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $31.1M $9.35M +$1.77M +23.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $29.3M $6.6M +$1.09M +19.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $28.2M $6.77M +$815K +13.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $27.4M $8.34M +$1.54M +22.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $25.9M $7.58M +$1.65M +27.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $24.2M $5.51M +$488K +9.71% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $23.7M $5.95M +$1.18M +24.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $22.5M $6.81M +$2.87M +72.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $19.7M $5.94M +$3.28M +123% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $16.4M $5.02M +$3.06M +155% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $13.3M $4.78M +$2.89M +153% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $10.5M $3.94M +$1.94M +97.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $8.51M $2.66M +$612K +29.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $7.9M $1.97M -$193K -8.94% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-15
Q3 2020 $8.09M $1.89M -$313K -14.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $8.41M $2M -$17K -0.85% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $8.42M $2.05M +$69K +3.49% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $8.35M $2.16M +$88K +4.25% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $8.27M $2.2M +$184K +9.12% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $8.08M $2.01M +$368K +22.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $7.71M $1.98M +$794K +67% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $6.92M $2.07M +$882K +74.1% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-10
Q3 2018 $6.04M $2.02M +$810K +67.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $5.23M $1.65M +$644K +64.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $4.58M $1.19M +$342K +40.6% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $4.24M $1.19M -$330K -21.7% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-10
Q3 2017 $4.57M $1.21M +$759K +169% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $3.81M $1M +$895K +844% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $2.92M $843K +$787K +1405% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $2.13M $1.52M Oct 1, 2016 Dec 31, 2016 10-K 2019-03-12
Q3 2016 $448K +$426K +1936% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 $106K +$85K +405% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 $56K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q3 2015 $22K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
Q2 2015 $21K Apr 1, 2015 Jun 30, 2015 10-Q 2016-09-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.